Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7AXR

Crystal structure of BRD4(1) bound to the dual BET-HDAC inhibitor LSH24

Summary for 7AXR
Entry DOI10.2210/pdb7axr/pdb
DescriptorBromodomain-containing protein 4, 4-acetyl-3-ethyl-N-(3-(3-(hydroxyamino)-3-oxopropyl)phenyl)-5-methyl-1H-pyrrole-2-carboxamide (3 entities in total)
Functional Keywordsbrd4(1), brd4, bd1, first bromodomain, bromodomain, bet, hdac, beti, hdaci, dual inhibitor, lsh24, protein binding
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight15814.19
Authors
Huegle, M. (deposition date: 2020-11-10, release date: 2021-10-06, Last modification date: 2024-01-31)
Primary citationSchaker-Hubner, L.,Warstat, R.,Ahlert, H.,Mishra, P.,Kraft, F.B.,Schliehe-Diecks, J.,Scholer, A.,Borkhardt, A.,Breit, B.,Bhatia, S.,Hugle, M.,Gunther, S.,Hansen, F.K.
4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
J.Med.Chem., 64:14620-14646, 2021
Cited by
PubMed Abstract: Multitarget drugs are an emerging alternative to combination therapies. In three iterative cycles of design, synthesis, and biological evaluation, we developed a novel type of potent hybrid inhibitors of bromodomain, and extra-terminal (BET) proteins and histone deacetylases (HDACs) based on the BET inhibitor and well-established HDAC inhibitors. The most promising new hybrids, and , displayed submicromolar inhibitory activity against HDAC1-3 and 6, and BRD4(1), and possess potent antileukemia activity. induced apoptosis more effectively than the combination of ricolinostat and birabresib (1:1). The most balanced dual inhibitor, , induced significantly more apoptosis than the related control compounds (no BRD4(1) affinity) and (no HDAC inhibition) as well as the 1:1 combination of both. Additionally, was well tolerated in an zebrafish toxicity model. Overall, our data suggest an advantage of dual HDAC/BET inhibitors over the combination of two single targeted compounds.
PubMed: 34582215
DOI: 10.1021/acs.jmedchem.1c01119
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.5 Å)
Structure validation

237735

数据于2025-06-18公开中

PDB statisticsPDBj update infoContact PDBjnumon